Anticipated $0.05 EPS for Sangamo Therapeutics, Inc. (SGMO) as of May, 9

April 17, 2018 - By Benjamin Allen

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.4. That’s change of 0.17, from 2017Q3’s 1.57. 16 investors sold all, 42 reduced holdings as Sangamo Therapeutics, Inc. ratio fall. 46 grew stakes while 35 funds bought stakes. Funds hold 53.22 million shares thus 2.49% more from 2017Q3’s 51.93 million shares.
State Board Of Administration Of Florida Retirement Systems holds 0% or 61,070 shs in its capital. Ubs Asset Americas Incorporated accumulated 37,122 shs. Schwab Charles Mgmt Inc holds 0.01% or 433,717 shs. Millennium Mgmt Lc has invested 0.01% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Granahan Investment Ma invested in 155,704 shs or 0.2% of the stock. Moreover, Prelude Cap Management Ltd Co has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Leisure invested in 40,715 shs or 0.55% of the stock. Wellington Group Limited Liability Partnership holds 0% or 132,502 shs in its capital. Clarivest Asset Mngmt Ltd Llc reported 127,521 shs. Raymond James Advsrs reported 18,962 shs. The Georgia-based Atlantic Trust Grp Ltd Co has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Vanguard Grp has 4.48 million shs. United Cap Advisers Limited invested in 32,314 shs. Group One Trading Limited Partnership stated it has 0.03% of its capital in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Spark Investment Ltd Llc, a New York-based fund reported 86,500 shs.

Sangamo Therapeutics, Inc. registered $2.30 million net activity with 0 insider buys and 13 insider sales since January 2, 2018. Mento Steven J sold 9,433 shs worth $219,546. The insider Herberts Curt A. III sold $258,894. Ramasastry Saira had sold 9,450 shs worth $235,080 on Monday, February 26. Yi Kathy had sold 5,000 shs worth $127,812.

Investors wait Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s quarterly earnings on May, 9., Zacks reports. This year’s earnings per share analyst estimate is anticipated to be $0.05. That is 121.74 % up compareed to $-0.23 earnings per share for last year. If earnings per share of $0.05 is announced the profit of SGMO could be $4.32 million giving it 89.50 P/E. -133.33 % EPS growth is what analysts predict. $-0.15 earnings per share was announced for last [previous quarter]. SGMO reached $17.9 on during the last trading session after $1.9 change.Sangamo Therapeutics, Inc. has 3.34 million shares volume, 45.98% up from normal. SGMO is uptrending and has moved 352.38% since April 17, 2017. SGMO outperformed the S&P500 by 340.83%.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Total analysts of 7 have positions in Sangamo Therapeutics (NASDAQ:SGMO) as follows: 6 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 86%. Since November 15, 2017 according to StockzIntelligence Inc Sangamo Therapeutics has 9 analyst reports. On Thursday, February 22 the stock has “Buy” rating by Jefferies. On Thursday, February 22 the rating was maintained by Piper Jaffray with “Buy”. On Wednesday, November 15 the company was upgraded by PiperJaffray. The company rating was maintained by Wedbush on Wednesday, November 15. On Tuesday, March 13 the company was maintained by Wedbush. In Thursday, February 22 report Wells Fargo maintained the stock with “Buy” rating. On Wednesday, January 3 the rating was maintained by Piper Jaffray with “Buy”.

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.The company has $1.55 billion market cap. The company's zinc finger DNA-binding protein technology enables specific genome editing and gene regulation.Last it reported negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.